the outcome of the Delhi High Court case brought by Roche against Biocon and Mylan in February gains significance. Roche has alleged that Biocon/Mylan has misrepresented its drugs as a biosimilar of its bestselling breast cancer drug, Trastuzumab (Herceptin), without having undergone the required
10.04 AM Jul 8th
version of Trastuzumab, in the Indian market until the disposal of the present suit, and also sought an injunction restraining the said defendants from relying upon or otherwise referring to HERCEPTIN®, HERCLONTM or BICELTIS® or any data relating to Trastuzumab marketed as HERCEPTIN®, HERCLONTM
10.48 PM Feb 8th
Source:Economic Times - NEW DELHI: Biocon`s launch of the world`s first bio-similar of Trastuzumab, a critical breast cancer drug, is unlikely to benefit patients in a big way if the company sticks to the prices it has indicated, claimed health activists on Monday. They allege that Roche, which
1.54 PM Jan 21st
Follow moneycontrol.comFacebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window Windows 8
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.